Abstract:Objective To analyze the clinical characteristics and antimicrobial resistance of Acinetobacter bauma-nnii (A. baumannii) isolated from blood specimens of 75 hospitals in Hebei Provincial Bacterial Resistance Surveillance System from 2016 to 2021. Methods Clinical distribution and change in antimicrobial resistance of A. baumannii isolated from blood specimens in Hebei Province from January 2016 to December 2021 were retrospectively analyzed by WHONET 5.6 and SPSS 24.0 software. Results From 2016 to 2021, 1 739 strains of A. baumannii were isolated from blood specimens in Hebei Province. The median age of patients was 64 years old, the ratio of male to female was 1.7 ∶1. The number of A. baumannii isolated from department of critical care medicine ranked first (769 strains, 44.2%), resistance rates to cephalosporin, compound preparations of β-lactamase inhibitors and carbapenes exceeded 75%; resistance rates of the strains isolated from outpatient and emergency departments to the above antibiotics agents exceeded 65%, ranking second only to the department of critical care medicine. Isolation rate of carbapenem-resistant A. baumannii (CRAB) increased from 55.9% in 2016 to 69.6% in 2019, and decreased by 9.0% in the following two years, isolation rate was 60.6% by 2021, and the cumulative isolation rate of CRAB increased by 4.7% in 6 years. Except for minocycline and polymyxin B, resistance rates of patients in different age groups to other common antimicrobial agents were significantly different (all P < 0.001); resistance rates of A. baumannii isolated from blood cultures of adult patients (≥15 years old) to common antimicrobial agents is generally higher than that of neonates and children (≤14 years old). Conclusion From 2016 to 2021, resistance rates of A. baumannii isolated from blood specimens in Hebei Province to common antimicrobial agents were high, especially in the department of critical care medicine and emergency department. Isolation rate of CRAB is on the rise, rational use of antimicrobial agents as well as prevention and control of healthcare-associated infection should continue to be strengthened.